Investor News
Psyence Group Corporate Update
Psyence Group Corporate Update
Psyence Taps Another Pharma Exec To Drive Its Clinical Program
Psyence Taps Another Pharma Exec To Drive Its Clinical Program TORONTO, May 31, 2022 – Psyence Group Inc. (CSE: PSYG | OTCQB: PSYGF) (“Psyence” or the “Company”), a life [...]
Psyence and Filament Health Enter Into Exclusive Licensing Agreements For Natural Psilocybin Products
Psyence and Filament Health Enter Into Exclusive Licensing Agreements For Natural Psilocybin Products The partnership leverages Psyence’s expertise in fungi cultivation and palliative care as well as Filament’s expertise [...]
Psyence Group Announces DTC Eligibility Approval in the U.S
TORONTO, 09 February 2022 – Psyence Group Inc. (CSE: PSYG | OTCQB: PSYGF) (“Psyence” or the “Company”), a life science biotechnology company pioneering the use of natural psychedelics in mental health and well-being, is pleased to announce that the Company’s common shares are now eligible for electronic clearing and settlement through the Depository Trust Company (“DTC”) in the United States (“US”).
Psyence Awarded ISO Certification through the British Standards Institute for its Natural Psilocybin Production Facility
Psyence’s facility, which is federally licensed to cultivate and export psilocybin mushrooms for the legal medical and research markets, is based in Southern Africa and has been operational since January 2021.
Psyence looks to expand capital market opportunities in the UK and Europe
TORONTO, DATE, 2022 – Psyence Group Inc. (CSE: PSYG | OTCQB: PSYGF) (“Psyence” or the “Company”), a life science biotechnology company pioneering the use of natural psychedelics in mental health and well-being, announces that it is investigating capital market opportunities to access a broader pool of United Kingdom (“UK”) and European investors. This includes a potential dual listing in the UK.
Investor News
Psyence Taps Another Pharma Exec To Drive Its Clinical Program
Psyence Taps Another Pharma Exec To Drive Its Clinical [...]
Psyence and Filament Health Enter Into Exclusive Licensing Agreements For Natural Psilocybin Products
Psyence and Filament Health Enter Into Exclusive Licensing Agreements [...]
Psyence to Present at the H.C Wainwright 2nd Annual Psychedelics Conference December 6
Psyence to Present at the H.C Wainwright 2nd Annual Psychedelics Conference December 6
Psyence Group Announces Private Placement
Psyence announces that it is commencing a non-brokered private placement offering of up to CAD$2,000,000 of unsecured convertible promissory notes (the “Notes”).
Psyence Group Functional Mushroom Brand “GOODMIND™” Commences National Roll-Out In South Africa’s Largest Coffee Retail Chain
Psyence is pleased to announce that its joint venture functional mushroom brand GOODMINDTM has partnered with one of Africa’s largest coffee retail chains, “vida e caffè”, to commence the rollout of its GOODMINDTM functional mushroom brand in select vida e caffè’s coffee shops in South Africa.
Psyence Group Invited as First Psychedelic Company to present at the 15th-Annual Global Wellness Summit
Psyence’s Head of Corporate Social Responsibility, Mary-Elizabeth Gifford, will host an in-person keynote conversation with Rick Doblin, PhD, Founder and Executive Director of the Multidisciplinary Association for Psychedelic Studies (MAPS) on the future of Psychedelics and Healing.
Why Psyence?
International expertise in palliative medicine and science
-
-
- Our scientific and medical team includes Dr. Clive Ward-Able, a pharmaceutical industry veteran with significant experience in the commercialization of a pharmaceutical product and direct involvement in designing and conducting clinical trials. Dr. Amza Ali, an internationally recognized neurologist, and Dr. Justin Grant, a leader in drug development.
- Psyence CEO Dr. Neil Maresky is physician and immediate past Vice President of Scientific Affairs at AstraZeneca Canada.
-
Extensive networks and partnerships
-
-
- We are building partnerships with a network of institutions and companies including:
- Government research centres
- University hospitals and research centres
- Regulatory stakeholders
- Non-governmental organizations (NGOs)
-
Extensive capital markets/business building experience
-
-
- Experienced global executive team
- Our capital markets team (Bayline Capital Partners) has a track record for creating shareholder value and achieving sustainable growth
-
An IP portfolio in cultivation and therapeutic products
-
-
- A mix of certified spores under cultivation
- Psilocybin-based formulations with a focus on the anxiety and mental issues that come with end stage cancer under development
-
Downloads
Financial Statements
Corporate Details
Why Psyence?
International expertise in palliative medicine and science
-
-
-
- Our scientific and medical team includes Dr. Clive Ward-Able, a pharmaceutical industry veteran with significant experience in the commercialization of a pharmaceutical product and direct involvement in designing and conducting clinical trials. Dr. Amza Ali, an internationally recognized neurologist, and Dr. Justin Grant, a leader in drug development.
- Psyence CEO Dr. Neil Maresky is physician and immediate past Vice President of Scientific Affairs at AstraZeneca Canada.
-
-
Extensive networks and partnerships
-
-
-
- We are building partnerships with a network of institutions and companies including:
- Government research centres
- University hospitals and research centres
- Regulatory stakeholders
- Non-governmental organizations (NGOs)
-
-
An IP portfolio in cultivation and therapeutic products
-
-
-
- A mix of certified spores under cultivation
- Psilocybin-based formulations with a focus on the anxiety and mental issues that come with end stage cancer under development
-
-
Investor Sign-Up
Please enter your details below to receive investor updates on Psyence Group